A PHASE Ib/II OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY ACTIVITY AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC NON?SMALL CELL LUNG CANCER WITH A K

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Nsclc
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1) Valid results from either central testing of tissue or local testing of blood or tissue documenting the presence of the KRAS G12C mutation
    2. 2) Valid results from either central or local testing of tissue documenting expression of PD-L1
    3. 3) Histologically or cytologically documented locally advanced unresectable or metastatic NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy

You may not be eligible for this study if the following are true:

    1. 1) Inability or unwillingness to swallow pills
    2. 2) Malabsorption syndrome or other condition that would interfere with enteral absorption
    3. 3) Pulmonary lymphoepithelioma-like carcinoma subtype of NSCLC



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.